REPORT SCOPE
INTRODUCTION
OBJECTIVES OF REVIEW
This review provides an in-depth look at the most promising major biologics (blood, blood components and derivatives, allergenics and vaccines) that include biotechnology based drugs and products (therapeutic proteins, recombinant DNA vaccines, gene therapies, and devices).
Drivers and resistors of the global biotech pharma market have been discussed with reference to product, region and technology specific factors. Individual product profiles are included. We explore how biotechnology based pharma industry works, has grown over the years and the key factors that contribute to its growth. While the industry is undeniably global, it is impossible to understand it without regional knowledge. Therefore, we will explore Canadian, European and Asia/Pacific markets besides U.S. All in all, this review will serve as a one-stop data bank for biotech enthusiasts.
AUDIENCE FOR REVIEW
The advent of biotechnology has allowed for tremendous strides in the discovery, development, and commercialization of novel therapeutics, vaccines and new chemical entities by both biotechnology and pharma companies. While biotechnology offers research institutions and companies a myriad of options for the development of these therapeutics, it has become clear that two development platforms have taken on a leading role. Therapeutic proteins and therapeutic antibodies collectively comprise almost 75% of the biotechnology drugs currently on the market and the new chemical entities, or NCEs, rule rest of the market. With this review, we will provide background on these development platforms, their respective applications, and potential market opportunities for drugs emerging from them.
This review will define the drivers and resistors of the global biotech pharma market with reference to product, region and technology specific factors. It explores how biotechnology based pharmaceutical industry works and has grown over the years.
The information and analysis offered through this review is an important asset in decision-making for managers and consultants in the pharmaceutical and biotechnology industry and for young entrepreneurs planning for biotech startup ventures.
SCOPE AND CONTENT
This review provides a comprehensive evaluation of the most promising major biologics (blood, blood components and derivatives, allergenics and vaccines) that include biotechnology based drugs and products (therapeutic proteins, recombinant DNA vaccines, gene therapies, devices).
This review gives you access to:
- Explanation of the concept and role of biotechnology based products in pharmaceutical industry.
- Analysis of the benchmarking categories: Therapeutic proteins, gene therapies, blood components and derivatives, vaccines, allergenics, devices.
- Critical analysis of marketed products and R&D products in each category.
- Market trends.
- Description of the key stages in the drug development pathway that a new drug candidate has to go through.
- In depth evaluation of the main technologies in biotechnology research: bioinformatics, genomics, microarrays, proteomics, and pharmacogenomics.
- Overview of biotechnology based pharmaceutical industry in the U.S., Europe, Canada and Asia/Pacific focused on key therapy areas, promising approved products, technologies and regional product approval agencies/guidelines.
- Analysis of key medical conditions that drive biotechnology based research and drug development, comparison with available standard hormonal/chemical treatments for the same.
- Company focused evaluation of major players in the industry - forecasts and business strategies.
METHODOLOGY AND INFORMATION SOURCES
The sales data included is sourced from publicly available documents. Products whose sales data is not disclosed by companies have not been included in estimates and forecasts.
ASSUMPTIONS
While projections can only be as good as the data available to calculate them, certain assumptions must still be made even with reliable data. The assumptions that are implicit in a forecasting model profoundly influence the forecasts. Our analysis is based on the following assumptions:
- The products included in the estimations and forecasts are the major drivers of the market.
- Sales data from the previous years was reviewed assuming that the past trends will continue in the future.
- Where sales data for a full year was unavailable an estimate of the full year sales was made.
The criteria for including companies in this review are: the companies have to be publicly traded, have to involve in R&D of human therapeutics derived from biological substance, have to apply genetic engineering, molecular biology, structural chemistry, rational drug design or rDNA technology. Companies dedicated to developing testing equipments or assays are excluded.
Company and product information in this review was assimilated from company-provided documents including annual reports, form 10-K, press reports, and government websites such as SEC and FDA. Discussions with company executives and managers are also a part of the review. Key information on commercial potential and market sizes was obtained from industry professionals.
The technological information and analysis presented in this review is based on a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations.
